| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 30.73M | 93M | 216.87M |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 2.94M | 24.58M | 49.01M |
| SG&A % of Revenue | - | - | - |
| Research & Development | 27.79M | 68.42M | 167.87M |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 |
| Operating Income | -30.73M | -93M | -216.87M |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -2.03% | -1.33% |
| EBITDA | -39.78M | -83.98M | -216.68M |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | -1.11% | -1.58% |
| D&A (Non-Cash Add-back) | 0 | 9.02M | 189K |
| EBIT | -39.78M | -83.98M | -216.87M |
| Net Interest Income | -9.06M | 9.02M | 34.74M |
| Interest Income | 92K | 9.02M | 34.74M |
| Interest Expense | 9.15M | 0 | 0 |
| Other Income/Expense | -9.06M | 9.02M | 34.74M |
| Pretax Income | -39.78M | -83.98M | -182.13M |
| Pretax Margin % | - | - | - |
| Income Tax | 0 | 0 | 18K |
| Effective Tax Rate % | 1% | 1% | 1% |
| Net Income | -39.78M | -83.98M | -182.15M |
| Net Margin % | - | - | - |
| Net Income Growth % | - | -1.11% | -1.17% |
| Net Income (Continuing) | -39.78M | -83.98M | -182.15M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -0.79 | -1.66 | -3.30 |
| EPS Growth % | - | -1.1% | -0.99% |
| EPS (Basic) | -0.79 | -1.66 | -3.30 |
| Diluted Shares Outstanding | 50.67M | 50.66M | 55.19M |
| Basic Shares Outstanding | 50.67M | 50.66M | 55.19M |
| Dividend Payout Ratio | - | - | - |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Total Current Assets | 152.06M | 398.41M | 529.71M |
| Cash & Short-Term Investments | 151.89M | 395.46M | 520.65M |
| Cash Only | 151.89M | 118.32M | 141.79M |
| Short-Term Investments | 0 | 277.14M | 378.86M |
| Accounts Receivable | 0 | 1.21M | 4.7M |
| Days Sales Outstanding | - | - | - |
| Inventory | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | 57K | 0 | 1.74M |
| Total Non-Current Assets | 0 | 3M | 224.24M |
| Property, Plant & Equipment | 0 | 2.59M | 13.32M |
| Fixed Asset Turnover | - | - | - |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 210.42M |
| Other Non-Current Assets | 0 | 401K | 498K |
| Total Assets | 152.06M | 401.4M | 753.95M |
| Asset Turnover | - | - | - |
| Asset Growth % | - | 1.64% | 0.88% |
| Total Current Liabilities | 9.98M | 20.56M | 28.56M |
| Accounts Payable | 418K | 2.14M | 1.07M |
| Days Payables Outstanding | - | - | - |
| Short-Term Debt | 0 | 1.1M | 3.23M |
| Deferred Revenue (Current) | 0 | 0 | 0 |
| Other Current Liabilities | 515K | 17.15M | 22.36M |
| Current Ratio | 15.24x | 19.38x | 18.55x |
| Quick Ratio | 15.24x | 19.38x | 18.55x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 0 | 933K | 8.6M |
| Long-Term Debt | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 933K | 8.6M |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 |
| Total Liabilities | 9.98M | 21.49M | 37.16M |
| Total Debt | 0 | 2.03M | 11.83M |
| Net Debt | -151.89M | -116.28M | -129.96M |
| Debt / Equity | - | 0.01x | 0.02x |
| Debt / EBITDA | - | - | - |
| Net Debt / EBITDA | - | - | - |
| Interest Coverage | -3.36x | - | - |
| Total Equity | 142.07M | 379.91M | 716.79M |
| Equity Growth % | - | 1.67% | 0.89% |
| Book Value per Share | 2.80 | 7.50 | 12.99 |
| Total Shareholders' Equity | 142.07M | 379.91M | 716.79M |
| Common Stock | 2.25M | 0 | 1K |
| Retained Earnings | -39.78M | -123.77M | -305.92M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 2.14M | 329K | 915K |
| Minority Interest | 0 | 0 | 0 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Cash from Operations | -16.43M | -74.76M | -171.17M |
| Operating CF Margin % | - | - | - |
| Operating CF Growth % | - | -3.55% | -1.29% |
| Net Income | -39.78M | -83.98M | -182.15M |
| Depreciation & Amortization | 0 | 0 | 189K |
| Stock-Based Compensation | 2.14M | 6.1M | 23.33M |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | 11.4M | -2.98M | -10.55M |
| Working Capital Changes | 9.81M | 6.11M | -2M |
| Change in Receivables | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 418K | 1.61M | -1.07M |
| Cash from Investing | 0 | -273.91M | -300.46M |
| Capital Expenditures | 0 | -167K | -1.15M |
| CapEx % of Revenue | - | - | - |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | 0 | 0 | 0 |
| Cash from Financing | 168.32M | 315.39M | 495.11M |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | 0 | 0 | 1.63M |
| Net Change in Cash | - | - | - |
| Free Cash Flow | -16.43M | -74.93M | -172.33M |
| FCF Margin % | - | - | - |
| FCF Growth % | - | -3.56% | -1.3% |
| FCF per Share | -0.32 | -1.48 | -3.12 |
| FCF Conversion (FCF/Net Income) | 0.41x | 0.89x | 0.94x |
| Interest Paid | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Return on Equity (ROE) | -28% | -32.18% | -33.22% |
| Return on Invested Capital (ROIC) | - | -54.96% | -38.25% |
| Debt / Equity | - | 0.01x | 0.02x |
| Interest Coverage | -3.36x | - | - |
| FCF Conversion | 0.41x | 0.89x | 0.94x |
Apogee Therapeutics, Inc. (APGE) grew revenue by 0.0% over the past year. Growth has been modest.
Apogee Therapeutics, Inc. (APGE) reported a net loss of $253.7M for fiscal year 2024.
Apogee Therapeutics, Inc. (APGE) has a return on equity (ROE) of -33.2%. Negative ROE indicates the company is unprofitable.
Apogee Therapeutics, Inc. (APGE) had negative free cash flow of $237.6M in fiscal year 2024, likely due to heavy capital investments.